Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Utility of targeted, amplicon-based deep sequencing to detect resistance to first-line tuberculosis drugs in Botswana.

Wang Q, Modongo C, Allender C, Engelthaler DM, Warren RM, Zetola NM, Shin SS.

Antimicrob Agents Chemother. 2019 Aug 12. pii: AAC.00982-19. doi: 10.1128/AAC.00982-19. [Epub ahead of print]

PMID:
31405858
2.

Clinical and Virological Outcomes of TB/HIV Coinfected Patients Treated With Dolutegravir-Based HIV Antiretroviral Regimens: Programmatic Experience From Botswana.

Modongo C, Wang Q, Dima M, Matsiri O, Kgwaadira B, Rankgoane-Pono G, Shin SS, Zetola NM.

J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):111-115. doi: 10.1097/QAI.0000000000002126.

PMID:
31335593
3.

Undetected tuberculosis at enrollment and after hospitalization in medical and oncology wards in Botswana.

Baik Y, Fane O, Wang Q, Modongo C, Caiphus C, Grover S, Zetola NM, Shin SS.

PLoS One. 2019 Jul 11;14(7):e0219678. doi: 10.1371/journal.pone.0219678. eCollection 2019.

4.

Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study.

Mehta K, Ravimohan S, Pasipanodya JG, Srivastava S, Modongo C, Zetola NM, Weissman D, Ivaturi V, Gumbo T, Bisson GP, Vinnard C.

J Antimicrob Chemother. 2019 Oct 1;74(10):2994-3002. doi: 10.1093/jac/dkz265.

PMID:
31273386
5.

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D.

Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Review.

6.

Mixed Mycobacterium tuberculosis-Strain Infections Are Associated With Poor Treatment Outcomes Among Patients With Newly Diagnosed Tuberculosis, Independent of Pretreatment Heteroresistance.

Shin SS, Modongo C, Baik Y, Allender C, Lemmer D, Colman RE, Engelthaler DM, Warren RM, Zetola NM.

J Infect Dis. 2018 Nov 5;218(12):1974-1982. doi: 10.1093/infdis/jiy480.

PMID:
30085153
7.

High rates of exposure to tuberculosis patients among HIV-infected health care workers in Botswana.

Shin SS, Modongo C, Zetola NM, Wang Q, Phologolo T, Kestler M, Ho-Foster A.

Int J Tuberc Lung Dis. 2018 Apr 1;22(4):366-370. doi: 10.5588/ijtld.17.0376.

8.

Geospatial modelling in guiding health program strategies in resource-limited settings-the way forward.

Gu D, Modongo C, Shin SS, Zetola NM.

Ann Transl Med. 2017 Dec;5(24):499. doi: 10.21037/atm.2017.10.16. No abstract available.

9.

Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatment.

Zentner I, Modongo C, Zetola NM, Pasipanodya JG, Srivastava S, Heysell SK, Mpagama S, Schlect HP, Gumbo T, Bisson GP, Vinnard C.

Int J Infect Dis. 2018 Mar;68:18-23. doi: 10.1016/j.ijid.2017.12.017. Epub 2017 Dec 15.

10.

Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation.

Vinnard C, Ravimohan S, Tamuhla N, Pasipanodya J, Srivastava S, Modongo C, Zetola NM, Weissman D, Gumbo T, Bisson GP.

PLoS One. 2017 Nov 2;12(11):e0187624. doi: 10.1371/journal.pone.0187624. eCollection 2017.

11.

Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB.

Vinnard C, Ravimohan S, Tamuhla N, Pasipanodya J, Srivastava S, Modongo C, Zetola NM, Weissman D, Gumbo T, Bisson GP.

J Antimicrob Chemother. 2017 Jul 1;72(7):2020-2027. doi: 10.1093/jac/dkx111.

12.

Diagnosis of pulmonary tuberculosis and assessment of treatment response through analyses of volatile compound patterns in exhaled breath samples.

Zetola NM, Modongo C, Matsiri O, Tamuhla T, Mbongwe B, Matlhagela K, Sepako E, Catini A, Sirugo G, Martinelli E, Paolesse R, Di Natale C.

J Infect. 2017 Apr;74(4):367-376. doi: 10.1016/j.jinf.2016.12.006. Epub 2016 Dec 22.

13.

Molecular, Spatial, and Field Epidemiology Suggesting TB Transmission in Community, Not Hospital, Gaborone, Botswana.

Surie D, Fane O, Finlay A, Ogopotse M, Tobias JL, Click ES, Modongo C, Zetola NM, Moonan PK, Oeltmann JE; Kopanyo Study Group.

Emerg Infect Dis. 2017 Mar;23(3):487-490. doi: 10.3201/eid2303.161183. Epub 2017 Mar 15.

14.

Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.

Vinnard C, Ravimohan S, Tamuhla N, Ivaturi V, Pasipanodya J, Srivastava S, Modongo C, Zetola NM, Weissman D, Gumbo T, Bisson GP.

Br J Clin Pharmacol. 2017 Apr;83(4):801-811. doi: 10.1111/bcp.13172. Epub 2016 Dec 9.

15.

High Treatment Success Rates Among HIV-Infected Multidrug-Resistant Tuberculosis Patients After Expansion of Antiretroviral Therapy in Botswana, 2006-2013.

Shin SS, Modongo C, Boyd R, Caiphus C, Kuate L, Kgwaadira B, Zetola NM.

J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):65-71. doi: 10.1097/QAI.0000000000001169.

16.

Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients.

Modongo C, Pasipanodya JG, Magazi BT, Srivastava S, Zetola NM, Williams SM, Sirugo G, Gumbo T.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5928-32. doi: 10.1128/AAC.00962-16. Print 2016 Oct.

17.

Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis.

Srivastava S, Modongo C, Siyambalapitiyage Dona CW, Pasipanodya JG, Deshpande D, Gumbo T.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5922-7. doi: 10.1128/AAC.00961-16. Print 2016 Oct.

18.

Protocol for a population-based molecular epidemiology study of tuberculosis transmission in a high HIV-burden setting: the Botswana Kopanyo study.

Zetola NM, Modongo C, Moonan PK, Click E, Oeltmann JE, Shepherd J, Finlay A.

BMJ Open. 2016 May 9;6(5):e010046. doi: 10.1136/bmjopen-2015-010046.

19.

The impact of mixed infections on the interpretation of molecular epidemiology studies of tuberculosis.

Shin SS, Modongo C, Zetola NM.

Int J Tuberc Lung Dis. 2016 Mar;20(3):423-4. doi: 10.5588/ijtld.15.1024. No abstract available.

20.

Identification of a Large Pool of Microorganisms with an Array of Porphyrin Based Gas Sensors.

Zetola NM, Modongo C, Mathlagela K, Sepako E, Matsiri O, Tamuhla T, Mbongwe B, Martinelli E, Sirugo G, Paolesse R, Di Natale C.

Sensors (Basel). 2016 Apr 1;16(4):466. doi: 10.3390/s16040466.

21.

A Locus at 5q33.3 Confers Resistance to Tuberculosis in Highly Susceptible Individuals.

Sobota RS, Stein CM, Kodaman N, Scheinfeldt LB, Maro I, Wieland-Alter W, Igo RP Jr, Magohe A, Malone LL, Chervenak K, Hall NB, Modongo C, Zetola N, Matee M, Joloba M, Froment A, Nyambo TB, Moore JH, Scott WK, Lahey T, Boom WH, von Reyn CF, Tishkoff SA, Sirugo G, Williams SM.

Am J Hum Genet. 2016 Mar 3;98(3):514-524. doi: 10.1016/j.ajhg.2016.01.015.

22.

Collision of Three Pandemics: The Coexistence of Cervical Cancer, HIV Infection, and Prior Tuberculosis in the Sub-Saharan Country of Botswana.

Zetola NM, Grover S, Modongo C, Chiyapo SP, Nsingo-Bvochora M, Narasimhamurthy M, Lin LL, Jarvis J, Shin SS, Robertson E.

J Glob Oncol. 2016 Jan 13;2(1):47-50. doi: 10.1200/JGO.2015.001701. eCollection 2016 Feb.

23.

Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients.

Modongo C, Pasipanodya JG, Zetola NM, Williams SM, Sirugo G, Gumbo T.

Antimicrob Agents Chemother. 2015 Oct;59(10):6337-43. doi: 10.1128/AAC.01050-15. Epub 2015 Jul 27.

24.

Erratum: Longer hospital stay is associated with high rates of tuberculosis-related morbidity and mortality within 12 months after discharge in a referral hospital in Sub-Saharan Africa.

Zetola NM, Macesic N, Shin SS, Peloso A, Ncube R, Klausner JD, Modongo C, Collman RG.

BMC Infect Dis. 2015 May 10;15:211. doi: 10.1186/s12879-015-0942-8. No abstract available.

25.

Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss.

Modongo C, Sobota RS, Kesenogile B, Ncube R, Sirugo G, Williams SM, Zetola NM.

BMC Infect Dis. 2014 Oct 9;14:542. doi: 10.1186/1471-2334-14-542.

26.

Advanced immune suppression is associated with increased prevalence of mixed-strain Mycobacterium tuberculosis infections among persons at high risk for drug-resistant tuberculosis in Botswana.

Shin SS, Modongo C, Ncube R, Sepako E, Klausner JD, Zetola NM.

J Infect Dis. 2015 Feb 1;211(3):347-51. doi: 10.1093/infdis/jiu421. Epub 2014 Jul 28.

28.

Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB/RIF are associated with poor clinical outcomes.

Zetola NM, Shin SS, Tumedi KA, Moeti K, Ncube R, Nicol M, Collman RG, Klausner JD, Modongo C.

J Clin Microbiol. 2014 Jul;52(7):2422-9. doi: 10.1128/JCM.02489-13. Epub 2014 Apr 30.

29.

Clinical outcomes among persons with pulmonary tuberculosis caused by Mycobacterium tuberculosis isolates with phenotypic heterogeneity in results of drug-susceptibility tests.

Zetola NM, Modongo C, Moonan PK, Ncube R, Matlhagela K, Sepako E, Collman RG, Bisson GP.

J Infect Dis. 2014 Jun 1;209(11):1754-63. doi: 10.1093/infdis/jiu040. Epub 2014 Jan 16.

30.

Examining the relationship between alcohol use and high-risk sex practices in a population of women with high HIV incidence despite high levels of HIV-related knowledge.

Zetola NM, Modongo C, Olabiyi B, Ramogola-Masire D, Collman RG, Chao LW.

Sex Transm Infect. 2014 May;90(3):216-22. doi: 10.1136/sextrans-2013-051244. Epub 2014 Jan 15.

31.

Impact of the human immunodeficiency virus on early multidrug-resistant tuberculosis treatment outcomes in Botswana.

Hafkin J, Modongo C, Newcomb C, Lowenthal E, MacGregor RR, Steenhoff AP, Friedman H, Bisson GP.

Int J Tuberc Lung Dis. 2013 Mar;17(3):348-53. doi: 10.5588/ijtld.12.0100. Epub 2013 Jan 14.

32.

Prevalence of hypothyroidism among MDR-TB patients in Botswana.

Modongo C, Zetola NM.

Int J Tuberc Lung Dis. 2012 Nov;16(11):1561-2. doi: 10.5588/ijtld.12.0403. No abstract available.

33.

Alcohol use and abuse among patients with multidrug-resistant tuberculosis in Botswana.

Zetola NM, Modongo C, Kip EC, Gross R, Bisson GP, Collman RG.

Int J Tuberc Lung Dis. 2012 Nov;16(11):1529-34. doi: 10.5588/ijtld.12.0026. Epub 2012 Sep 7.

34.

Measuring stigma: are we looking in the right places?

Zetola NM, Olabiyi B, Ramogola-Masire D, Modongo C.

Int J Tuberc Lung Dis. 2012 Aug;16(8):1130-1. doi: 10.5588/ijtld.11.0824. No abstract available.

35.

Has the answer to diagnosing TB in resource-limited settings been found?

Modongo C, Zetola NM, Pandori M, Klausner JD.

MLO Med Lab Obs. 2011 Mar;43(3):25. No abstract available.

Supplemental Content

Loading ...
Support Center